Literature DB >> 24659120

Otological findings in pediatric patients with hypogammaglobulinemia.

Marzieh Tavakol1, Ali Kouhi2, Hassan Abolhassani3, Alireza Ghajar4, Mohsen Afarideh5, Shervin Shahinpour6, Asghar Aghamohammadi7.   

Abstract

The main clinical presentation of patients with primary antibody deficiency (PAD) incorporates upper respiratory tract infections comprising otitis media, sinusitis and pneumonia. This study was designed to investigate clinical and paraclinical otological complications in major types of PAD. A cross sectional study was conducted on 55 PAD patients with diagnosis of selective IgA deficiency, common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), and hyper IgM syndrome. All patients underwent otological examinations, audiometry, and auditory brain stem response. Otological complications were detected in 54.5% of PAD patients. Conductive hearing loss was the main finding amongst PID patients (73.3%) followed by sensorineural hearing loss which was present in 8 cases. Otitis media with effusion (21.8%), chronic otitis media (27.2%), tympanosclerosis with intact tympanic membrane (5.4%) and auditory neuropathy (3.6%) were most important found complications. CVID and XLA patients with prophylactic usage of antibiotics had lower rate of audiological complications (p=0.04) and otitis media with effusion (p=0.027). As our results showed, asymptomatic otological findings were not rare in PAD patients; therefore, a systematic otological investigation is recommended as an integral part of the management and follow-up of these patients.

Entities:  

Mesh:

Year:  2014        PMID: 24659120

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  1 in total

Review 1.  Does the type of rhinitis influence development of otitis media with effusion in children?

Authors:  Nicola Quaranta; Lucia Iannuzzi; Matteo Gelardi
Journal:  Curr Allergy Asthma Rep       Date:  2014-11       Impact factor: 4.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.